Emerald Mutual Fund Advisers Trust Has $2.37 Million Position in Senseonics Holdings Inc (SENS)

Emerald Mutual Fund Advisers Trust increased its holdings in Senseonics Holdings Inc (NYSEAMERICAN:SENS) by 33.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 497,420 shares of the company’s stock after acquiring an additional 125,000 shares during the period. Emerald Mutual Fund Advisers Trust owned about 0.28% of Senseonics worth $2,373,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC purchased a new stake in Senseonics in the 2nd quarter valued at about $74,936,000. BlackRock Inc. increased its stake in Senseonics by 1,958.6% in the 2nd quarter. BlackRock Inc. now owns 3,811,007 shares of the company’s stock valued at $15,664,000 after buying an additional 3,625,877 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Senseonics in the 3rd quarter valued at about $14,703,000. PointState Capital LP purchased a new stake in Senseonics in the 2nd quarter valued at about $10,970,000. Finally, OppenheimerFunds Inc. purchased a new stake in Senseonics in the 2nd quarter valued at about $7,926,000. Institutional investors own 30.66% of the company’s stock.

Shares of SENS stock opened at $3.83 on Friday. The company has a current ratio of 2.93, a quick ratio of 2.81 and a debt-to-equity ratio of 0.76. Senseonics Holdings Inc has a 12-month low of $2.41 and a 12-month high of $5.29.

Senseonics (NYSEAMERICAN:SENS) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.09). Senseonics had a negative return on equity of 406.72% and a negative net margin of 828.76%. The company had revenue of $3.62 million for the quarter, compared to analysts’ expectations of $3.87 million. During the same quarter in the previous year, the business earned ($0.12) EPS. The company’s revenue for the quarter was up 345.1% on a year-over-year basis. As a group, equities research analysts forecast that Senseonics Holdings Inc will post -0.54 EPS for the current year.

Several equities research analysts have commented on the stock. Dougherty & Co began coverage on shares of Senseonics in a research note on Friday, August 24th. They issued a “buy” rating and a $6.00 price objective for the company. BTIG Research restated a “buy” rating and set a $6.00 price target on shares of Senseonics in a research note on Thursday, August 9th. Six equities research analysts have rated the stock with a buy rating, Senseonics presently has an average rating of “Buy” and a consensus price target of $6.00.

Senseonics Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Further Reading: What are the benefits of a balanced fund?

Institutional Ownership by Quarter for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply